Print this page    •   Back to Web version of article

Worldwide Antiretroviral Drug Sales 2006*

September 2007

DrugCompany$ MillionChange From 2005Notes
TruvadaGilead1,194+210%
KaletraAbbott1,135+13%
CombivirGlaxoSmithKline977-8%
ReyatazBristol-Myers Squibb931+34%
SustivaBristol-Myers Squibb791+16%Includes $76 million related to Atripla sales
VireadGilead689-12%
TrizivirGlaxoSmithKline496-10%
EpzicomGlaxoSmithKline446+207%
EpivirGlaxoSmithKline374-11%
ViramuneBoehringer-Ingelheim353-4%Estimate, based on 276 Euros
CrixivanMerck327-6%
FuzeonRoche250+19%Estimate, based on 312 Swiss Francs
Lexiva/AgeneraseGlaxoSmithKline242+19%
ZiagenGlaxoSmithKline216-13%
AtriplaGilead206-Gilead recorded 100% of Atripla sales, then paid BMS $76 million for the efavirenz
ZeritBristol-Myers Squibb155-18%
Invirase/FortovaseRoche145+28%Estimate, based on 182 Swiss Francs
AptivusBoehringer-Ingelheim67-Estimate, based on 53 Euros
EmtrivaGilead36-13%
TOTAL
9,030+14%
* Does not include unreported drugs (Videx, Norvir, Viracept, Rescriptor, Retrovir)

Source: AIDSMeds.com based on SEC filings.


Back to the TAGline September 2007 contents page.




This article was provided by Treatment Action Group. It is a part of the publication TAGline. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art44507.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.